AR063601A1 - Arilamidas sustituidas por tiazol u oxazol - Google Patents
Arilamidas sustituidas por tiazol u oxazolInfo
- Publication number
- AR063601A1 AR063601A1 ARP070104958A ARP070104958A AR063601A1 AR 063601 A1 AR063601 A1 AR 063601A1 AR P070104958 A ARP070104958 A AR P070104958A AR P070104958 A ARP070104958 A AR P070104958A AR 063601 A1 AR063601 A1 AR 063601A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- heteroaryl
- hydrogen
- Prior art date
Links
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004429 atom Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 102100040479 P2X purinoceptor 2 Human genes 0.000 abstract 1
- 101710189968 P2X purinoceptor 2 Proteins 0.000 abstract 1
- 102100040460 P2X purinoceptor 3 Human genes 0.000 abstract 1
- 101710189970 P2X purinoceptor 3 Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se proporcionan también métodos para utilizar los compuestos en el tratamiento de enfermedades, en ellas los compuestos actúan como antagonistas de receptores P2X3 y/o P2X2/3 y métodos para la obtención de los compuestos de interés. Reivindicación 1: Un compuesto de la fórmula 1, o sales farmacéuticamente aceptables del mismo, en la que: R1 es un grupo de la fórmula A o fórmula B; en las que: X es -S- u -O-; y Ra y Rb con independencia entre sí son hidrógeno; alquilo C1-6, alcoxi C1-6, alquil C1-6-sulfonil-alquilo C1-6, halo-alquilo C1-6, halo-alcoxi C1-6, hetero-alquilo C1-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, aminocarbonilo; alcoxi C1-6carbonilo; o ciano; o Ra y Rb junto con el átomo, al que están unidos, pueden formar un grupo fenilo, que está opcionalmente sustituido, R2 es fenilo opcionalmente sustituido; piridinilo opcionalmente sustituido; pirimidinilo opcionalmente sustituido; piridazinilo opcionalmente sustituido; o tiofenilo opcionalmente sustituido; R3 es hidrógeno; alquilo C1-6, hetero-alquilo C1-6 o ciano; R4 es hidrógeno; alquilo C1-6 o hetero-alquilo C1-6; o R3 y R4 junto con el átomo al que están unidos pueden formar un anillo carbocíclico C3-6, R5 es alquilo C1-6, hetero- alquilo C1-6, halo-alquilo C1-6, N-(alquil C1-6)amino; N,N-di-(alquil C1-6)-amino; cicloalquilo C3-7; arilo; heteroarilo; heterociclilo; cicloalquil C3-7-alquilo C1-6, aril-alquilo C1-6, heteroaril-alquilo C1-6, heterociclil-alquilo C1-6, heterocicliloxi; ariloxi-alquilo C1-6, -(CRcRd)rn-C(O)-R8 en el que: m es 0 o 1; Rc y Rd con independencia entre sí son hidrógeno; o alquilo C1-6, y R8 es hidrógeno; alquilo C1-6 hetero-alquilo C1-6 cicloalquilo C3-7; arilo; heteroarilo; heterociclilo; cicloalquil C3-7-alquilo C1-6; aril-alquilo C1-6; heteroaril-alquilo C1-6; heterociclil-alquilo C1-6; cicloalquiloxi C3-7; ariloxi; heteroariloxi; heterocicliloxi; cicloalquiloxi C3-7-alquilo C1-6; ariloxi-alquilo C1-6; heteroariloxi- alquilo C1-6, heterocicliloxi-alquilo C1-6; o -NR9R10, en el que; R9 es hidrógeno; o alquilo C1-6 y R10 es hidrógeno; alquilo C1-6, hetero-alquilo C1-6; cicloalquilo C3-7; arilo; heteroarilo; heterociclilo; cicloalquil C3-7-alquilo C1-6, aril- alquilo C1-6, heteroaril-alquilo C1-6 o heterociclil-alquilo C1-6, o R4 y R5 junto con el átomo al que están unidos forman un anillo carbocíclico C3-6, que está opcionalmente sustituido por hidroxi; o R4 y R5 junto con el átomo al que están unidos forman un anillo heterocíclico C4-6 que contienen uno o dos heteroátomos elegidos con independencia entre sí entre O, N y S; o R3, R4 y R5 junto con el átomo al que están unidos forman un heteroarilo de seis eslabones que tiene uno dos átomos de N y que está opcionalmente sustituido por halógeno, amino o alquilo C1-6; R6 es alq1uilo C1-6, alquiloxi C1-6; halógeno; haloalquilo C1-6, halo-alcoxi C1-6, o ciano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85828306P | 2006-11-09 | 2006-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063601A1 true AR063601A1 (es) | 2009-02-04 |
Family
ID=39149180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104958A AR063601A1 (es) | 2006-11-09 | 2007-11-07 | Arilamidas sustituidas por tiazol u oxazol |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7786110B2 (es) |
| EP (1) | EP2091927B1 (es) |
| JP (1) | JP5084839B2 (es) |
| KR (2) | KR101152714B1 (es) |
| CN (1) | CN101528717B (es) |
| AR (1) | AR063601A1 (es) |
| AT (1) | ATE517097T1 (es) |
| AU (1) | AU2007316681B2 (es) |
| BR (1) | BRPI0718714B8 (es) |
| CA (1) | CA2668399C (es) |
| CL (1) | CL2007003192A1 (es) |
| ES (1) | ES2367455T3 (es) |
| IL (1) | IL198301A (es) |
| MX (1) | MX2009004900A (es) |
| PE (1) | PE20081475A1 (es) |
| TW (1) | TW200829584A (es) |
| WO (1) | WO2008055840A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0718714B8 (pt) | 2006-11-09 | 2021-05-25 | Hoffmann La Roche | arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende |
| US8501933B2 (en) * | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
| JP2011502148A (ja) * | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| US8461185B2 (en) | 2007-10-31 | 2013-06-11 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| BRPI0820838B8 (pt) * | 2007-12-17 | 2021-05-25 | Hoffmann La Roche | derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3 |
| CA2708791C (en) * | 2007-12-17 | 2016-06-21 | F. Hoffmann-La Roche Ag | Imidazole-substituted arylamides and uses thereof as p2x receptor antagonists |
| ES2541662T3 (es) * | 2007-12-17 | 2015-07-23 | F. Hoffmann-La Roche Ag | Derivados arilamida sustituidos con triazol y utilización de los mismos como antagonistas de receptores purinérgicos P2X3 y/o P2X2/3 |
| ES2417182T3 (es) * | 2007-12-17 | 2013-08-06 | F. Hoffmann-La Roche Ag | Nuevas arilamidas sustituidas con pirazol |
| EP2262766B1 (en) | 2008-02-29 | 2015-11-11 | Evotec AG | Amide compounds, compositions and uses thereof |
| US20110237578A1 (en) | 2008-09-18 | 2011-09-29 | Zhi-Liang Wei | Amide compounds, compositions and uses thereof |
| EP2379518B1 (en) * | 2008-12-16 | 2014-05-07 | F. Hoffmann-La Roche AG | Thiadiazole-substituted arylamides |
| JP5465782B2 (ja) * | 2009-06-22 | 2014-04-09 | エフ．ホフマン−ラ ロシュ アーゲー | 新規オキサゾロン及びピロリジノン置換アリールアミド |
| SG177308A1 (en) | 2009-06-22 | 2012-02-28 | Hoffmann La Roche | Novel biphenyl and phenyl-pyridine amides |
| EP2575815A4 (en) * | 2010-06-04 | 2013-12-25 | Albany Molecular Res Inc | GLYCIN TRANSPORTER 1 INHIBITORS, METHODS OF MAKING THE SAME, AND USES THEREOF |
| US8698952B2 (en) | 2011-10-31 | 2014-04-15 | Lg Innotek Co., Ltd. | Camera module |
| JP6310936B2 (ja) * | 2012-12-07 | 2018-04-11 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | Ｎ−（イソオキサゾール−３−イル）−アリール−カルボン酸アミド類及び除草剤としてのそれらの使用 |
| EP2905282A1 (en) * | 2014-02-05 | 2015-08-12 | AXXAM S.p.A. | Substituted thiazole or oxazole as P2X7 receptor antagonists |
| US10183937B2 (en) | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| CA2969952A1 (en) | 2014-12-09 | 2016-06-16 | Adam James Davenport | 1,3-thiazol-2-yl substituted benzamides |
| KR20160138877A (ko) | 2015-05-26 | 2016-12-06 | (주)펠리테크 | 마이크로파를 이용한 세라믹 발열 하이브리드 건조기 |
| WO2018052772A1 (en) | 2016-09-15 | 2018-03-22 | Boehringer Ingelheim International Gmbh | Heteroaryl carboxamide compounds as inhibitors of ripk2 |
| CN116854693A (zh) * | 2016-09-30 | 2023-10-10 | 阿沙纳生物科学公司 | P2x3和/或p2x2/3化合物及方法 |
| WO2020002090A1 (de) | 2018-06-25 | 2020-01-02 | Bayer Aktiengesellschaft | Substituierte thiazolylpyrrolone sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| EP3757103A1 (en) * | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
| CN115884970B (zh) * | 2020-09-24 | 2025-09-23 | 中国医药研究开发中心有限公司 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020002193A1 (en) | 1999-03-25 | 2002-01-03 | Yu Dingwei Tim | Thiadiazole antifungal agents |
| DK1194421T3 (da) | 1999-06-30 | 2006-02-13 | Lundbeck & Co As H | Selektive NPY (Y5) antagonister |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| CZ301182B6 (cs) | 2000-05-26 | 2009-12-02 | Idenix (Cayman) Limited | Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry |
| HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| EA200400648A1 (ru) * | 2001-11-08 | 2005-04-28 | Элан Фармасьютикалз, Инк. | N, n'-замещенные производные 1,3-диамино-2-гидроксипропана |
| CA2488842A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Carbocyclic nucleoside analogs as rna-antivirals |
| TW200500375A (en) | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| WO2004002422A2 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| ES2624353T3 (es) | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| EP1620089A4 (en) | 2003-03-26 | 2008-12-24 | Crc For Asthma Ltd | Therapeutic and prophylactic compositions and their uses |
| CA2522476A1 (en) | 2003-04-18 | 2004-11-04 | Merck & Co., Inc. | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| JP4731468B2 (ja) * | 2003-05-12 | 2011-07-27 | ファイザー・プロダクツ・インク | Ｐ２ｘ７受容体のベンズアミド阻害剤 |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| ATE478886T1 (de) | 2003-07-25 | 2010-09-15 | Idenix Pharmaceuticals Inc | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c |
| HRP20120901T1 (hr) * | 2004-03-05 | 2012-12-31 | F. Hoffmann - La Roche Ag | Diaminopirimidini kao p2x3 i p2x2/3 |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| BRPI0714315B8 (pt) * | 2006-06-29 | 2021-05-25 | Hoffmann La Roche | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende |
| BRPI0718714B8 (pt) | 2006-11-09 | 2021-05-25 | Hoffmann La Roche | arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende |
| JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
-
2007
- 2007-10-31 BR BRPI0718714A patent/BRPI0718714B8/pt active IP Right Grant
- 2007-10-31 JP JP2009535681A patent/JP5084839B2/ja active Active
- 2007-10-31 CN CN2007800394586A patent/CN101528717B/zh active Active
- 2007-10-31 KR KR1020097009417A patent/KR101152714B1/ko active Active
- 2007-10-31 MX MX2009004900A patent/MX2009004900A/es active IP Right Grant
- 2007-10-31 AT AT07822118T patent/ATE517097T1/de active
- 2007-10-31 EP EP07822118A patent/EP2091927B1/en active Active
- 2007-10-31 CA CA2668399A patent/CA2668399C/en active Active
- 2007-10-31 ES ES07822118T patent/ES2367455T3/es active Active
- 2007-10-31 KR KR1020127002496A patent/KR101165936B1/ko active Active
- 2007-10-31 AU AU2007316681A patent/AU2007316681B2/en not_active Ceased
- 2007-10-31 WO PCT/EP2007/061771 patent/WO2008055840A1/en not_active Ceased
- 2007-11-06 TW TW096141899A patent/TW200829584A/zh unknown
- 2007-11-06 CL CL200703192A patent/CL2007003192A1/es unknown
- 2007-11-07 PE PE2007001531A patent/PE20081475A1/es not_active Application Discontinuation
- 2007-11-07 AR ARP070104958A patent/AR063601A1/es unknown
- 2007-11-08 US US11/983,225 patent/US7786110B2/en active Active
-
2009
- 2009-04-22 IL IL198301A patent/IL198301A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007003192A1 (es) | 2008-06-20 |
| US7786110B2 (en) | 2010-08-31 |
| CA2668399A1 (en) | 2008-05-15 |
| KR20090086073A (ko) | 2009-08-10 |
| AU2007316681B2 (en) | 2013-01-24 |
| CN101528717B (zh) | 2013-04-24 |
| KR101152714B1 (ko) | 2012-06-18 |
| KR101165936B1 (ko) | 2012-07-19 |
| ES2367455T3 (es) | 2011-11-03 |
| WO2008055840A1 (en) | 2008-05-15 |
| PE20081475A1 (es) | 2008-10-18 |
| US20080132494A1 (en) | 2008-06-05 |
| ATE517097T1 (de) | 2011-08-15 |
| AU2007316681A1 (en) | 2008-05-15 |
| IL198301A0 (en) | 2010-02-17 |
| JP5084839B2 (ja) | 2012-11-28 |
| KR20120034766A (ko) | 2012-04-12 |
| BRPI0718714A2 (pt) | 2013-11-26 |
| EP2091927B1 (en) | 2011-07-20 |
| CN101528717A (zh) | 2009-09-09 |
| EP2091927A1 (en) | 2009-08-26 |
| BRPI0718714B8 (pt) | 2021-05-25 |
| BRPI0718714B1 (pt) | 2020-09-29 |
| IL198301A (en) | 2013-06-27 |
| MX2009004900A (es) | 2009-05-19 |
| CA2668399C (en) | 2015-01-27 |
| TW200829584A (en) | 2008-07-16 |
| JP2010509264A (ja) | 2010-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063601A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| AR061667A1 (es) | Arilamidas sustituidas con tetrazol | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| ES2515194T3 (es) | Derivados de pirrolidina | |
| ES2543567T3 (es) | Métodos de utilización de inhibidores de ALK | |
| AR073136A1 (es) | Compuestos de pirrol | |
| AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR061844A1 (es) | Pirimidil-ciclopentanos como inhibidores de protein-quinasa akt | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| AR078463A1 (es) | Composicion y metodo para controlar plagas de artropodos | |
| AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
| AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
| AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
| AR086554A1 (es) | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| AR076401A1 (es) | Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5) | |
| AR066603A1 (es) | Derivados de arilamida pirimidona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |